BlackRock
UROV

BlackRock’s Urovant Sciences Ltd. UROV Stock Holding History

BlackRock’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,668
Closed -$398K – 5400
2020
Q4 		$398K Sell
24,668
-46,718
-65% -$579K ﹤0.01% 4379
2020
Q3 		$667K Sell
71,386
-238,720
-77% -$2.12M ﹤0.01% 4211
2020
Q2 		$3.05M Buy
310,106
+4,617
+2% +$44.3K ﹤0.01% 3704
2020
Q1 		$2.82M Buy
305,489
+15,219
+5% +$183K ﹤0.01% 3554
2019
Q4 		$4.5M Buy
290,270
+4,730
+2% +$51.3K ﹤0.01% 3537
2019
Q3 		$2.7M Buy
285,540
+2,065
+0.7% +$17.9K ﹤0.01% 3654
2019
Q2 		$2.24M Buy
283,475
+1,183
+0.4% +$9.71K ﹤0.01% 3736
2019
Q1 		$2.84M Buy
282,292
+51,173
+22% +$525K ﹤0.01% 3589
2018
Q4 		$1.52M Sell
231,119
-150,000
-39% -$1.36M ﹤0.01% 3762
2018
Q3 		$4.57M Buy
+381,119
New +$4.51M ﹤0.01% 3525

BlackRock's UROV Position: Q1 2021 in Review

BlackRock sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 24,668 shares — an estimated $398K sold.

BlackRock first reported a position in UROV in Q3 2018 and held it in 10 quarters. The position peaked at $4.57M in Q3 2018. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

  • BlackRock reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
  • BlackRock sold 24,668 Urovant Sciences Ltd. shares in Q1 2021, an estimated $398K.
  • BlackRock first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 10 quarters.
  • BlackRock's Urovant Sciences Ltd. position peaked at $4.57M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.